• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

by jtcir-auto | Apr 25, 2022 | Press Releases

– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease (“PD”), a neurodegenerative movement disorder TORONTO, ONTARIO, April 25, 2022 (GLOBE NEWSWIRE)...

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

by jtcir-auto | Apr 19, 2022 | Press Releases

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April 19, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris...

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

by jtcir-auto | Apr 19, 2022 | Press Releases

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April 19, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris...

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

by jtcir-auto | Apr 12, 2022 | Press Releases

– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

by jtcir-auto | Apr 12, 2022 | Press Releases

– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

by jtcir-auto | Apr 11, 2022 | Press Releases

– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need TORONTO, ONTARIO, April 11, 2022 (GLOBE NEWSWIRE)...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow